Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
Arechar HealthCare
3x10 tablet
Imatinib mesylate
Keep in cold place
Delivering To:
Overview
Imatinib mesylate 400mg Tablet belongs to a class of medication known as tyrosine kinase inhibitors. It is an anticancer medicine that is commonly prescribed to treat certain blood cancers like chronic myeloid leukemia & acute lymphocytic leukemia, and gastrointestinal stromal tumors. It works as a specific inhibitor of several tyrosine kinase enzymes. After the oral administration, the effect of this medicine can be observed in 2-4 hours.
Blood Cancer
Like any other medicine, Imatinib mesylate 400mg Tablet also has some adverse effects on the body, and most of them are manageable without special medical attention.
Some common side effects include:
Difficulty in breathing
Indigestion
Constipation
Weight loss
Acidic stomach
Change in taste
Dry mouth
Joint pain
Irregular heartbeat
Unusual bleeding
Presence of blood in coughing
Abdominal pain.
Swelling around the eyes
Do not forget to discuss the risks and benefits of this medication with your doctor. Seek medical attention immediately in case of any severe issues.
TakeImatinib mesylate 400mg Tablet as prescribed by your doctor. Swallow it as a whole with water and don't chew, crush, or break it. This tablet should be taken with food. Take it at the same time every day for effective results.
Alcohol
unsafe
The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking Imatinib 400mg Tablet.
Pregnancy
consult your doctor
Do not take Imatinib 400mg Tablet without consulting the doctor in case of pregnancy.
Breast Feeding
consult your doctor
Imatinib 400mg Tablet is unsafe to use during breastfeeding as it may cause toxicity to the baby. It is safe if prescribed.
Driving
danger
Imatinib 400mg Tablet may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving or operating heavy machinery.
Kidney
caution
Consumption of Imatinib 400mg Tablet should be avoided without informing the doctor if you have any kidney-related issues.
Liver
caution
Consumption of Imatinib 400mg Tablet should be avoided without informing the doctor if you have any liver-related issues.
It is advisable not to miss a dose of Imatinib 400mg Tablet. If you miss a scheduled dose of this medicine, contact your doctor immediately.
Imatinib tablet is used to treat certain types of cancer, such as chronic myeloid leukemia, acute lymphocytic leukemia, and gastrointestinal stromal tumors.
This is an anti-cancer medication. This medication belongs to a class of medicines known as tyrosine kinase inhibitors. This medicine stops the growth of cancer cells and also prevents the multiplication of cancer cells.
Some common side effects of the Imatinib tablet are abdominal pain, fatigue, anxiety, vomiting, muscle pain, nausea, rash, joint pain, difficulty in breathing, etc.
It is not known whether it is safe or not. Please consult your doctor before consuming alcohol while taking this medicine.
This medicine is not recommended for breastfeeding unless it is necessary.
1.https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf
2.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf
3.Cohen, M. H., Johnson, J. R., & Pazdur, R. (2005). US Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clinical cancer research, 11(1), 12-19.
4.Nikolova, Z., Peng, B., Hubert, M., Seiberling, M., Keller, U., Ho, Y. Y., ... & Capdeville, R. (2004). Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. Cancer chemotherapy and pharmacology, 53(5), 433-438.
Devi, N. A., Hadi, M. A., Rajitha, P., Sharma, J. V. C., & Rao, A. S. (2013). Formulation and evaluation of floating controlled release tablets of imatinib mesylate using hydrophilic matrix system. Int J Pharm Pharm Sci, 5(1), 271-277.
Arechar HealthCare
Written By
Venika Choudhary
Medical Content Writer @ Magicine Pharma
I hold an M.Sc. in Microbiology and have a strong academic foundation in microbial sciences and applied biotechnology. I began my career with extensive hands-on research at CSIR laboratories, focusing on fungal enzyme production, studying fungal diversity in various ecosystems, and developing bio-pesticides as sustainable alternatives to chemical pesticides. This work deepened my understanding of fungal biology, bioactive compounds, and their pharmaceutical and agricultural applications. Transitioning from research, I now work as a medical content writer, where I combine my scientific expertise with a passion for clear and reliable healthcare communication. I apply my research background to create patient-friendly, compliant content for pharmaceutical companies and healthcare platforms, ensuring science is both trustworthy and accessible. Specializing in clear, accurate, and engaging content, I help patients make informed decisions and support pharmaceutical companies in delivering trusted information. Whether writing product descriptions, crafting disease awareness articles, or composing drug information leaflets, I consistently meet regulatory standards and address audience needs, making my content an asset for healthcare brands.
Reviewed By
Dr. Aditya Sarin - MBBS, MD, DrNB - Consultant Medical Oncology
Dr. Aditya Sarin, MBBS, MD, DrNB, is a highly qualified medical oncologist with profound research and clinical expertise, currently working at Sir Ganga Ram Hospital, New Delhi. He is also a member of the European Society of Medical Oncology (ESMO), a non-profit European organization dedicated to eradicating cancer by promoting comprehensive cancer care and advancing medical oncology. He has been honored with several awards, including the International Cancer Foundation scholarship (ESMO congress, 2022) and Young Medical Oncologist of the Year (Times of India, 2024). He is well-known for his breakthrough in oncology. Dr. Sarin is passionate about converting complex health information into a concise and clear form that is understandable to everyone, aiming to create awareness and cancer care among people.